Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
| العنوان: | Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer |
|---|---|
| المؤلفون: | Tatsuya Imabayashi, Keiko Tanimura, Nobuyo Tamiya, Naoko Okura, Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Akihiro Yoshimura, Sachi Harita, Junji Uchino, Naoya Nishioka, Yoshiko Kaneko, Yusuke Chihara, Koichi Takayama |
| المصدر: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 8, Iss 4, p 450 (2019) Volume 8 Issue 4 |
| بيانات النشر: | MDPI AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, psoas major muscle area, medicine.medical_treatment, lcsh:Medicine, Disease, Article, sarcopenia, 03 medical and health sciences, 0302 clinical medicine, PD-L1, Internal medicine, medicine, Lung cancer, non-small cell lung cancer, 030304 developmental biology, 0303 health sciences, biology, business.industry, lcsh:R, Red blood cell distribution width, General Medicine, Immunotherapy, musculoskeletal system, medicine.disease, body regions, Malnutrition, 030220 oncology & carcinogenesis, Sarcopenia, biology.protein, Non small cell, red blood cell distribution width, business, human activities |
| الوصف: | Secondary sarcopenia is defined as a decrease in muscle mass due to disease or malnutrition. Several studies have reported that secondary sarcopenia is an indicator of postoperative recurrence. We hypothesized that there is a correlation between the effect of immune checkpoint inhibitors (ICIs) and sarcopenia. We retrospectively analyzed 38 patients with advanced non-small cell lung cancer (NSCLC) who were treated with ICIs between February 2016 and April 2018. Patients were divided into two groups according to the change rate of the psoas major muscle area (PMMA) at the L2&ndash L3 position and investigated the correlation between the change rate of the PMMA and the efficacy of ICIs was investigated. The objective response and disease control rates were lower in patients with sarcopenia than in those without sarcopenia. Patients with sarcopenia exhibited a significantly shorter median progression-free survival (PFS) than non-sarcopenia patients. Moreover, focusing on good Eastern Cooperative Oncology Group performance status patients, sarcopenia patients showed a shorter PFS than non-sarcopenia patients. Patients with sarcopenia are associated with poor outcomes for immunotherapy among those with advanced NSCLC, based on retrospective analysis. Further research is needed to validate the clinical biomarkers involved in ICI responders. |
| وصف الملف: | application/pdf |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e513c954622f5501f93f91ced2497e71Test https://doi.org/10.3390/jcm8040450Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e513c954622f5501f93f91ced2497e71 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|